# A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

> **NCT00234429** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 74 (—)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Gefitinib, raltitrexed

## Key facts

- **NCT ID:** NCT00234429
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 74 (—)
- **Last updated:** 2007-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234429, "A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00234429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*